Current Treatment Strategies for Disseminated Candidiasis
3rd Dec 2005, 00:17 GMT
The incidence of disseminated candidiasis has increased dramatically over the past several decades. Fortunately, in recent years, a variety of new antifungal agents have become available to treat these infections. On the basis of efficacy, safety, and cost considerations, fluconazole is the agent of choice for the empirical treatment of disseminated candidiasis in nonneutropenic, hemodynamically stable patients, unless a patient is suspected to be infected with an azole-resistant species (i.e., Candida glabrata or Candida krusei). For hemodynamically unstable or neutropenic patients, agents with broader species coverage, such as polyenes, echinocandins, or, possibly, voriconazole, are preferred for empirical treatment of candidemia. Modification of the initial, empirical regimen depends on the response to therapy and the subsequent identification of the species of the offending pathogen. Echinocandins or high-dose polyenes are preferred for the treatment of infections with C. glabrata or C. krusei. Central venous catheters should be removed from all patients who have disseminated candidiasis, if feasible, and antifungal therapy should be administered to all patients who have candidemia or proven candidiasis.
Current Treatment Strategies for Disseminated Candidiasis related news:
- More Linking Strategies To Consider — WebProNews: Top News RSS Feed
- Global survey on unmet needs in asthma treatment — OnMedica Latest News
- Search Engine Strategies Chicago Coverage Day Two — Search Engine Journal
- PanAfrica: Aids Strategies Must Be Revisited - UNAIDS — AllAfrica News: Health and Medicine
- Search Engine Strategies Chicago Live Coverage Day 1 — Search Engine Journal
- Patient with disseminated intravascular coagulation as the first manifestation of adenocarcinoma of the prostate. Risks of prostatic biopsy — Prostate Cancer and Prostatic Diseases
- Lebanon's post-conflict strategies debated — The Daily Star > Local News
- UNAids: 'Prevention strategies aren't working' — Mail & Guardian Online
- Watchdog says lifestyle can affect NHS treatment — www.politics.co.uk | Headlines
- Ananomouse Corporation Participates in the Formulation of Mass Disaster Strategies — PR Web - Breaking News Stories
Latest news from Clin Infect Dis Latest Articles:
- Clinical Reevaluation of the QuantiFERON TB-2G Test as a Diagnostic Method for Differentiating Active Tuberculosis from Nontuberculous Mycobacteriosis
- Comparative Biological and Clinical Outcomes after a Switch from a Virologically Unsuccessful First Protease Inhibitor-Containing Antiretroviral Combination to a 3-Drug Regimen Containing Efavirenz, Nevirapine, or Abacavir